Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer

被引：34
|
作者：
Awad, Mark M. [1 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 08期
关键词：
SARCOMATOID CARCINOMA; AMPLIFICATION; CRIZOTINIB; GEFITINIB; PATIENT; CBL; UBIQUITINATION; RESPONSIVENESS; CHEMOTHERAPY; SENSITIVITY;
D O I：
10.1200/JCO.2015.64.2777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：879 / +
页数：5
相关论文
共 50 条
  • [21] A c-met inhibitor in the treatment of metastatic non small cell lung cancer with c-met amplification.
    Zhang, Tongtong
    Li, Junling
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations
    Huang, Caiwen
    Zou, Qihua
    Liu, Hui
    Qiu, Bo
    Li, Qiwen
    Lin, Yongbin
    Liang, Ying
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (04)
  • [23] Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations
    Caiwen Huang
    Qihua Zou
    Hui Liu
    Bo Qiu
    Qiwen Li
    Yongbin Lin
    Ying Liang
    Current Treatment Options in Oncology, 2020, 21
  • [24] Optimized Detection of Unknown MET Exon 14 Skipping Mutations in Routine Testing for Patients With Non-Small-Cell Lung Cancer
    Sun, Rui
    Wang, Zhizhong
    Zhao, Jiuzhou
    Ren, Pengfei
    Ma, Jie
    Guo, Yongjun
    JCO PRECISION ONCOLOGY, 2023, 7
  • [25] Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer
    Fu, Le
    Guo, Wei
    Liu, Bingshan
    Sun, Linlin
    Bi, Zhenghong
    Zhu, Li
    Wang, Xinyan
    Liu, Bin
    Xie, Qian
    Li, Ke
    BIOMARKERS, 2013, 18 (02) : 126 - 135
  • [26] Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer
    Wu, Xue
    Zhang, Yaru
    Pang, Jiaohui
    Lin, Li
    Yin, Jiani C.
    Tang, Haimeng
    Shao, Yang
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
    Blaquier, Juan Bautista
    Recondo, Gonzalo
    DRUGS IN CONTEXT, 2022, 11
  • [28] MET Exon 14 Skipping in Non-Small Cell Lung Cancer
    Heist, Rebecca S.
    Shim, Hyo Sup
    Gingipally, Shalini
    Mino-Kenudson, Mari
    Le, Long
    Gainor, Justin F.
    Zheng, Zongli
    Aryee, Martin
    Xia, Junfeng
    Jia, Peilin
    Jin, Hailing
    Zhao, Zhongming
    Pao, Gwilliam
    Engelman, Jeffrey A.
    Iafrate, A. John
    ONCOLOGIST, 2016, 21 (04): : 481 - 486
  • [29] Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation
    Vanderick, Ariane
    Colinet, Benoit
    ACTA CLINICA BELGICA, 2024, 79 (02) : 148 - 151
  • [30] MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression
    Gimenez-Capitan, Ana
    Teixido, Cristina
    Aguado, Cristina
    Rodriguez, Sonia
    Bertran-Alamillo, Jordi
    Castellvi, Josep
    Yeste, Zaira
    Perez, Ana
    Rosell, Rafael
    Molina-Vila, Miguel Angel
    CANCER RESEARCH, 2017, 77
12345